E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Gestational Diabetes Mellitus |
|
E.1.1.1 | Medical condition in easily understood language |
High blood sugars during pregnancy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018210 |
E.1.2 | Term | Gestational diabetes mellitus |
E.1.2 | System Organ Class | 100000004868 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine if metformin (a) reduces the requirement for insulin or (b) reduces fasting glucose at gestational weeks 32 and 38. |
|
E.2.2 | Secondary objectives of the trial |
Additional secondary objectives of this study are to determine if metformin; delays the initiation of insulin; reduces the insulin dose required; impacts on maternal body weight, BMI, waist circumference, blood glucose status, insulin resistance status and metabolic syndrome postpartum; reduces the proportion of infants with morbidities; in addition to standard care reduces infant birth weight when compared to standard care alone; reduces the proportion of maternal morbidities when compared to standard care alone; in addition to standard care reduces excessive maternal gestational weight gain; to determine if women consider metformin a more acceptable treatment than insulin; to determine the cost, cost effectiveness, and budget impact of metformin in addition to standard care for gestational diabetes mellitus.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria: a) Willing and able to provide written informed consent b) Participants aged 18-50 years c) Pregnancy gestation up to 28 weeks (+ 6 days) confirmed by positive pregnancy test d) Singleton pregnancy as determined by scan e) Positive diagnosis of Gestational Diabetes Mellitus on a OGTT according to IADPSG criteria if any one of the following are achieved: a. Fasting glucose >/= 5.1mmol/l and <7mmol/l, or b. 1 hour post glucose load of >/=10mmol/l, or c. 2 hour post glucose load of >/=8.5 mmol/l and <11.1mmol/l f) Resident in the locality and intending to deliver within the trial site
|
|
E.4 | Principal exclusion criteria |
Exclusion Criteria: Women who meet any one or more of the following exclusion criteria will not be eligible to take part in the trial: a) Participants who have an established diagnosis of diabetes (Type 1, Type 2, Monogenic or secondary) b) Participants with a fasting glucose ≥ 7mmol/l or a 2h value ≥ 11.1 mmol/l c) Multiple pregnancies (twins, triplets etc.) as determined by scan d) Known intolerance to metformin e) Known contraindication to the use of metformin which include: i. renal insufficiency (defined as serum creatinine of greater than 130 µmol/L or creatinine clearance <60 ml/min) ii. moderate to severe liver dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal) iii. shock or sepsis, and iv. previous hypersensitivity to metformin f) Major congenital malformations or an abnormality deemed unsuitable for metformin by the site PI or attending consultant g) Known small for gestational age1 h) Known current gestational hypertension, pre-eclampsia, or ruptured membranes i) Participants who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements j) Participants with significant gastrointestinal problems such as severe vomiting, Crohn’s disease or colitis which will inadvertently affect absorption of the study drug k) Participants with congestive heart failure or history of congestive heart failure l) Participants with serious mental illness which would affect adherence to study medication or compliance with study protocol in the opinion of the investigator m) Women with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
1Small for gestational age (SGA) refers to fetal growth less than the 10th percentile (RCOG, 2014), or if foetal growth is deemed unsatisfactory by the treating obstetrician.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy outcome is a composite of: • Insulin initiation (Yes/No) • Fasting glucose value </=5.1 mmol/l and >5.1 mmol/l
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Insulin initiation will be measured at all time points throughout the trial Fasting glucose will be evaluated at gestational weeks 32 and 38. |
|
E.5.2 | Secondary end point(s) |
Secondary efficacy outcomes include: 1. Time to insulin initiation and insulin dose required 2. Maternal morbidity at delivery (hypertensive disorders, antepartum and postpartum haemorrhage, polyhydramnios) 3. Mode and time of delivery 4. Postpartum glucose status, insulin resistance, and metabolic syndrome 5. Postpartum BMI, gestational weight gain, and waist circumference 6. Infant birth weight 7. Neonatal height and head circumference at delivery 8. Neonatal morbidities (Need for neonatal care unit, respiratory distress, jaundice, congenital anomalies, Apgar score) 9. Neonatal hypoglycaemia (defined as plasma glucose <2.6 mmoL/L on one or more occasions starting 30-60 minutes after birth). 10. Cost effectiveness and budget impact of metformin treatment in addition to standard care 11. Treatment acceptability (DTSQ and Rowan questionnaires) 12. Quality of Life determined by EQ5D-5L questionnaire
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Time to insulin initiation and insulin dose required will be measured at all time points throughout the trial. Maternal morbidity, mode and time of delivery, infant birth weight, neonatal morbidities and hypoglycaemia, and neonatal height and head circumference will be measured at delivery. Postpartum BMI, gestational weight gain, waist circumference, glucose status, insulin resistance, and metabolic syndrome will be measured at 12-16 weeks post-partum. Cost effectiveness of metformin treatment in addition to standard care will be measured at 12 weeks post-partum. Treatment acceptability will be measured at week 12 post randomisation and at 4 weeks post-partum. Quality of Life determined by EQ5D-5L questionnaire measured at baseline, 4 weeks post-partum, and 12 weeks post-partum.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |